Comparison of lipid lowering effect of anagliptin and miglitol in patients with type 2 diabetes

Comparison of lipid lowering effect of anagliptin and miglitol in patients with type 2 diabetes - Comparison of lipid lowering effect of anagliptin and miglitol

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000021494

Enrollment

Registered

2016-03-28

Start date

2016-03-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Administration of anagliptin Administration of miglitol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with type 2 diabetes LDL-C (120mg/dL and over)

Exclusion criteria

Exclusion criteria: Patients treated with alpha glucosidase inhibitor, DPP-4 inhibitor, insulin, or glucagon like peptide-1receptor agonist. Patients with sever liver and kidney disfunction. Patients with pregnacy. Patients with history of ileus.

Design outcomes

Primary

Measure	Time frame
Low-density lipoprotein cholesterol (LDL-C)	—

Countries

Japan

Contacts

Public ContactEriko Shibata

Yokohama City University Department of Endocrinology and Metabolism

shibatae15@gmail.com045-787-2639

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026